Deadly Tick Virus Triggers Liver Cell Death Via Novel Iron-Autophagy Pathway
SFTSV hijacks RNA methylation to drive iron-dependent ferroptosis in liver cells, revealing a potential new antiviral therapy target.
Summary
Researchers discovered that severe fever with thrombocytopenia syndrome virus (SFTSV) induces a specialized form of cell death called ferroptosis in liver cells by exploiting an RNA modification (m6A) pathway. SFTSV infection increases m6A methylation on ATG5 mRNA, boosting autophagy-driven ferritin degradation (ferritinophagy), which releases toxic free iron and triggers oxidative liver damage. The viral NSs protein was identified as the key driver. Blocking ferroptosis with ferrostatin-1 both protected liver cells and suppressed viral replication in lab and animal models, suggesting ferroptosis inhibition as a promising therapeutic strategy for this high-mortality infectious disease.
Detailed Summary
Severe fever with thrombocytopenia syndrome (SFTS) is a tick-borne viral disease with significant mortality that causes multiorgan damage, particularly to the liver. Despite its growing public health importance, the cellular mechanisms underlying SFTSV-induced liver injury remained poorly understood. This study addresses that gap by identifying a novel molecular pathway linking RNA epigenetics, selective autophagy, and iron-dependent cell death.
The researchers demonstrated that SFTSV infection disrupts the classical antioxidant redox cycle in liver cells by downregulating key ferroptosis-protective proteins GPX4 and SLC7A11, reducing glutathione (GSH) levels, and simultaneously elevating reactive oxygen species (ROS) and lipid peroxidation marker malondialdehyde (MDA). These hallmarks collectively confirmed that ferroptosis—a regulated, iron-dependent form of cell death—is activated during SFTSV infection.
A central discovery was that SFTSV infection elevates N6-methyladenosine (m6A) modification on ATG5 mRNA. ATG5 is a critical autophagy gene, and its enhanced m6A modification increased its expression, accelerating ferritinophagy—the selective autophagic degradation of ferritin via the cargo receptor NCOA4. Ferritinophagy liberates labile ferrous iron (Fe²⁺) from ferritin heavy chain 1 (FTH1) stores, feeding the Fenton reaction and amplifying oxidative damage. Critically, mutating the m6A modification sites on ATG5 mRNA significantly rescued cells from SFTSV-induced ferritinophagy, confirming the causal role of this epigenetic mark.
The study further pinpointed the NSs (non-structural small) protein of SFTSV as the primary viral factor responsible for driving ferritinophagy. NSs is a known virulence factor and interferon antagonist, but this study reveals an additional pathogenic function in manipulating host RNA methylation and autophagic machinery.
Finally, treatment with ferrostatin-1 (Fer-1), a well-characterized ferroptosis inhibitor, protected liver cells from ferroptosis and significantly suppressed SFTSV replication in both cell culture and animal models. Liver injury markers (ALT/GPT and AST/GOT1) were reduced in vivo, supporting the translational relevance of ferroptosis inhibition as a therapeutic approach. These findings establish a mechanistic framework—m6A modification → ATG5 upregulation → ferritinophagy → free iron release → ferroptosis—as central to SFTSV-induced liver pathology and nominate this pathway as a targetable vulnerability.
Key Findings
- SFTSV infection downregulates GPX4 and SLC7A11 while raising ROS and MDA, confirming ferroptosis activation in liver cells.
- SFTSV elevates m6A methylation on ATG5 mRNA; mutating m6A sites significantly rescues ferritinophagy and ferroptosis.
- The viral NSs protein is identified as the primary driver of m6A-dependent ferritinophagy during SFTSV infection.
- Ferritinophagy via NCOA4-FTH1 axis releases toxic Fe²⁺, fueling oxidative liver damage during viral infection.
- Ferroptosis inhibitor ferrostatin-1 reduces liver injury and suppresses SFTSV replication in vitro and in vivo.
Methodology
The study used in vitro cell culture models of SFTSV infection alongside in vivo animal models to assess ferroptosis markers (GPX4, SLC7A11, GSH, ROS, MDA). m6A modification of ATG5 mRNA was analyzed, with site-directed mutagenesis to confirm functional relevance. Ferrostatin-1 was administered as a pharmacological intervention to evaluate therapeutic potential.
Study Limitations
The specific m6A writer/eraser enzymes responsible for ATG5 methylation after SFTSV infection are not fully characterized. The in vivo model details and the extent to which findings translate to human SFTS pathology require further validation in clinical samples.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.